logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Some aspects of cerebroprotective activity of 4-hydro xy-3,5-di-tretboutyle of cinnamic acid in ischemic damage of the brain in experiment

[Experimental medicine]
Andrei Voronkov; Vladimir Abaev; Eduard Oganesian; Dmitry Pozdnyakov;

Cerebroprotective properties of 4-hydroxy-3,5-di-tretboutyle cinnamic acid (ATACL) have been studied. It has been established that in the conditions of focal brain ischemia, ATACL contributes to the normalization of metabolic processes in the brain tissue: an increase in the utilization of glucose by 305.5% (p<0.02), a 281.3 % decrease in lactate formation (p<0.01), reduction of edema and necrosis zone by 5% (p<0.02) and 123.9 % (p<0.02), respectively. In this case, the effect of 4-hydroxy-3,5-di-tretboutyle cinnamic acid surpassed that of ethylmethyl hydroxypyridine succinate and thioctic acid and was comparable to the effect of Vinpocetine.

Download

References:
1. Voronkov A. V., Pozdnyakov D. I., Mamleev A. V. Sovremennye problemy nauki i obrazovaniya. – Modern problems of science and education. 2016;2. Available at: http:// www.science-education.ru/ru/article/view?id=24398
2. Nazarova L. E., D’yakova I. N. Meditsinskiy vestnik Bashkortostana. – Medical bulletin of Bashkortostan. 2011;3:133-135.
3. Alam M. A., Subhan N., Rahman M. M. Adv. Nutrit. 2014;5:404-417. doi: 10.3945/an.113.005603
4. Cha M.-Y., Cho H. J., Kim C. Hum. Molec. Genet. 2015;24:6492-6504. doi: 10.1093/hmg/ddv358
5. Cheng Y. L., Park J. S., Manzanero S., Choi Y., Baik S. H., Okun E., Gelderblom M., Fann D. Y., Magnus T., Launikonis B. S., Mattson M. P., Sobey C. G., Jo D. G., Arumugam T. V. Neurobiol. Dis. 2014;62:286-295. doi: 10.1016/j. nbd.2013.10.009
6. Culmsee C., Monnig J., Kemp B. E., Mattson M. P. J. Mol. Neurosci. 2001;17:45-58. doi: 10.1385/JMN:17:1:45
7. Lapchak P. A. Expert Opin. Investig. Drugs. 2011;20:13- 22. doi: 10.1517/13543784.2011.542410
8. Nunez-Figueredo Y., Ramirez-Sanchez J., Hansel G. Neuropharmacology. 2014;85:517-527. doi: 10.1016/j.neuropharm. 2014.06.009
9. Rao P. V., Gan S. H. Evidence-based Complementary and Alternative Medicine : eCAM. 2014. doi:10.1155/2014/642942
10. Weisová P., Alvarez S. P., Kilbride S. M., Anilkumar U., Baumann B., Jordán J., Bernas T., Huber H. J., Düssmann H., Prehn J. H. Translational Psychiatry. 2013;10:e317. doi: 10.1038/tp.2013.92

Keywords: ischemia, cerebroprotective, derivatives of cinnamic acid


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy